Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by yorgosGKon Apr 18, 2018 6:05pm
256 Views
Post# 27907578

Useful data

Useful data

I quickly put together an excel with all of the sell trades from broker 018 (Echelon Wealth).
You can downlaod it via the link below. They have been selling their debenture shares since March at all sorts of market prices. I have added the total averages and total shares sold (including today's session) at the top of the excel.

No one knows what they will do (or if they will do anything)....Heck they would of already got rid of all of them if they wanted to by now. Since by the looks of it, they are strategically letting go of them like this, we wll be able to absorb without a problem, the drop was simply the short positions taken. This stock has the liquid to absorb a measily 5M$ loan deal (I mean give me a break look at our competitors......all well over 200M shares-out and MILLIONS in debt with over $1 SP).

I think what will happen is we get a good fair market price back before they exercise the warrants and at that time period we will finally get the news to help with the share price that will shake the MJ sector. Lets hope this happens soon! (which I think it most lickely will).

Echelon essentially made a 5M investment into KALY - funds that our company needed to start phase 2 with (which is literally peanuts to what we are going to be). I can almost garuntee the shorts will cover the warrants and we can put this thing to rest once and for all. After all the longer Echelon holds the more they make...don't forget!
 

The Convertible Debentures will bear interest from the date of closing at 9.0% per annum, payable semi-annually in arrears on June 30, 2018 and thereafter semi-annually on the last day of June and December in each year

 

Anywho - there is no telling exactly what will happen (althought many signs point to a healthy recovery +). I do know %100 that KALY is a winner. CBD to cure and prevent GvHD is patented and will ultimatly get FDA approval. This is just the begining...Just look at the before and afters in their corprate guide! Not even going to get into the potential for CBD + Naproxon for pain killer. And finally the news - who knows!....I'd bet will be bigger than the pain killer NR.


For what its worth: 
018 Sales - KALYl

 

Bullboard Posts